 |
|
Latanoprost and Respiratory Function in Asthmatic Patients
Randomized, Double-Masked, Placebo-Controlled Crossover Evaluation
Jan Hedner, MD, PhD;
Bernt Everts, MD;
Christina Ström Möller, MD
Arch Ophthalmol. 1999;117:1305-1309.
Objective To evaluate the effects of single and multiple administrations of the ocular hypotensive drug latanoprost on respiratory function, asthma symptoms, and use of asthma medication in patients with bronchial asthma.
Methods Twenty-four stable patients with asthma (forced expiratory volume in 1 second: 70% to 90% of predicted and a minimum of 10% reversibility after inhalation of albuterol sulfate) with no previous exposure to inhaled corticosteroids participated in this randomized, double-masked crossover trial. Patients received latanoprost, 0.005%, or placebo, 1 drop per day, in each eye during two 6-day treatment periods separated by a 2-week washout period. Acute latanoprost or placebo provocation, methacholine chloride airway reactivity, and  2-stimulator reversibility tests were performed.
Main Outcome Measures Morning and evening peak expiratory flow, spirometric performance throughout treatment periods and during different provocation tests, asthma symptoms, and use of asthma medications were evaluated.
Results There were no statistically significant differences between treatments in morning and evening peak expiratory flow, scored daytime and nocturnal asthma symptoms, or daily consumption of asthma medication. During placebo provocation, there was a small increase in forced expiratory volume in 1 second that was not seen during latanoprost provocation. This small difference (-0.09 L) was statistically significant but without clinical importance.
Conclusions Resting and provoked airway function and asthma symptoms were unaffected by latanoprost treatment in patients with asthma with no previous exposure to corticosteroids. Latanoprost can be used in patients with glaucoma and concomitant bronchial asthma.
From the Department of Clinical Pharmacology, Sahlgrenska University Hospital, Göteborg (Drs Hedner and Everts); and Pharmacia & Upjohn, Stockholm (Dr Ström Möller), Sweden. The authors have no financial or proprietary interest in the products mentioned.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Effect of Latanoprost on Regional Blood Flow and Capillary Permeability in the Monkey Eye
Johan Stjernschantz, Göran Selén, Maria Astin, Maritha Karlsson, and Bahram Resul
Arch Ophthalmol. 1999;117(10):1363-1367.
ABSTRACT
| FULL TEXT
Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 1999;117(10):1452.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
From PGF2{{alpha}}-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan The Proctor Lecture
Stjernschantz
IOVS 2001;42:1134-1145.
FULL TEXT
No Relationship Between Advertising and Editorial Acceptance
Hoffman and McDonnell
Arch Ophthalmol 2001;119:308-308.
FULL TEXT
|
